



HTA Rapid Reviews

The Global Evidence Synthesis Initiative



What are they? How to do it?

How can they improve decision making?

Agustín Ciapponi

Cochrane Argentina Director, Instituto de Efectividad Clínica

y Sanitaria (IECS), Argentina

- SR/HTAs take unacceptably long time but information is needed now!
- Rapid reviews/HTAs have emerged as an approach to synthesizing evidence, for informing decision makers in health care settings.
- It is uncertain if much shorter timeframe could be adequate to capture properly the key evidence.





Traditional systematic reviews





Rapid reviews



- SR and HTA (6 months to ~3 years)
- technology assessment report (6-9 months)
- rapid assessment (6 months)
- accelerated SR (4 months)
- rapid review (3 months)
- **tech notes** (6 weeks 6 months)
- technology overview (3 months)
- rapid response (1 week 1 month)
- mini HTA (month?)
- rapid HTA (2-4 weeks)
- quick note (5-7 days)
- **ultra rapid response** (hours days)
- scope searches (1/2 day)













Days Weeks Months Years

Scoping Rapid review HTA /Review
Ultra-rapid Rapid HTA
Response

How do we develop a procedure for the best available answer within a proper timeframe?




Gernot Wagner^{1*}, Barbara Nussbaumer-Streit¹, Judith Greimel², Agustín Ciapponi³ and Gerald Gartlehner^{1,4}

RESEARCH ARTICLE

Open Access

CrossMark



325 (58.5%) of 556 decision-makers and guideline developers worldwide completed our survey.



Traditional Systematic Review, 18 months (100%)



Rapid Review, 3 months (90%), 10% error tolerance



Rapid Review, <1 month



Background

- Several agencies increasingly do rapid reviews/responses (23 out of 25 surveyed agencies did rapid reviews in 2006)
 But they varied in:
 - methodology
 - -search strategy
 - —quality assessment
 - -restriction on study type
 - Analysis
 - Economic evaluations



IECS Setting

- IECS is an Argentinean HTA agency, that provides reports to public institutions, social security and private insurance entities.
- Since 2012 we produce <u>Ultra-rapid HTAs</u>, made in up to 3 days, aiming to solve specific coverage problems, often related to a single patient needs.
- The rapid-HTAs allow a more exhaustive assessment of the PICO question applicable to similar patients.
- Decision-makers systematically complete a brief survey on usefulness and satisfaction within two weeks of receiving the <u>Ultra-rapid HTAs</u>.





Ultra-rapid HTA (produced in 2-3 days)

1. ≠ Conclusions, amount and direction of the evidence?



Rapid-HTA (produced in 4-8 weeks)

- **2.a** What is the decision-makers' perception about <u>ultra-rapid HTAs?</u>
- **2.b** Which is the agreement between coverage decisions and <u>ultra-rapid HTAs</u>' conclusions



Main features of HTAs





Elaboration time	2-3 days	4-8 weeks	
Developer training	High	Moderate-High	
Supervision	1 Senior tutor	Whole HTA team	
Previous scoping	Not formally	Yes	
Focused search	Highly	Moderately	
Evidence source	SRs, CPGs, HTAs, Coverage policies, complementary primary studies		



Methods

- We selected pair of documents (ultra-rapid HTAs & rapid-HTAs) oriented to the same research question.
- All the rapid-HTAs were published after the ultra-rapid HTAs, within the following 12 months.
- The additional evidence identified by the rapid-HTAs, which was compiled at a later search date than the ultrarapid HTA, was excluded and the conclusions modified wherever necessary.
- Pairs of independent researchers extracted outcomes, and disagreements were solved by a third researcher.
- We analyzed the routine survey to study decision-makers' perception and compared their coverage decision against the conclusions of the reports.

We selected 32 pairs of documents and **24** that met inclusion criteria were finally included.

11....92% of rapid-HTAs included more evidence than ultrarapid-HTAs

Included Evidence	ultra-rapid-HTAs (Mean ± SD)	rapid-HTAs (Mean ± SD)	Difference (95% CI)	P value (t test)
Guidelines	2	5.5 ± 5.5	3.5 (1.2 - 5.8)	0.0043
Systematic Reviews	1.7 ± 1.5	3.4 ± 3.5	2.2 (0.6 - 3.8)	0.0071
RCTs	0.2 ± 0.7	1.1 ± 1.2	0.9 (0.3 - 1.5)	0.0028

The rapid-HTAs included 50% more safety and quality of life outcomes than ultra-rapid-HTAs in this sample




there was a 96% (95% CI 78.9 to 99.9) of conclusion matching with ultra-rapid-HTAs

The only one mismatch was because a rapid-HTAs considered a technology for selected cases and ultra-rapid-HTAs considered the same technology as experimental.




- 11 From May 2014 to February 2016 we collected a total of 68 responses from 117 reports (58%).
- The 3 most frequently consultations were related to cancer, neurological and musculoskeletal disorders; and half of the cases were related to drugs.
- In 10% of the cases had pending coverage decisions (all conclusions).




Usefulness

Neither useful nor useless 4%






Influence






Decision improvement






Results: Satisfaction





Agreement between coverage decision and repots' conclusions





Conclusions

- We found no serious mismatching between ultra-rapid HTAs & rapid-HTAs.
- Although ultra-rapid HTAs included less amount of evidence and in this sample not reported important outcomes as safety and quality of life, ultra-rapid HTAs seem to be a reliable source for the short-term decision-making.
- Most decision makers found ultra-rapid HTAs useful and their final decisions were influenced and improved by them.
- Agreement with final decisions was high.



Discussion

- The timeframe to produce evidence is becoming shorter: from quick and dirty to quick and best
- It is critical to determine that ultra-rapid-HTAs produced by highly trained teams are also reliable for the short-term decision-making in other setting.
- Although there was a high conclusion-matching, the "slower"evidence synthesis are still useful since they provide a more complete evidence picture and a possibly better informed decisionmaking.







Need for standardization!









http://www.iecs.org.ar/centro-cochrane-iecs/

